\documentclass[twocolumn,twoside]{article}
\makeatletter\if@twocolumn\PassOptionsToPackage{switch}{lineno}\else\fi\makeatother

\usepackage{amsfonts,amssymb,amsbsy,latexsym,amsmath,tabulary,graphicx,times,xcolor}

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% Following additional macros are required to function some 
% functions which are not available in the class used.
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
\usepackage{url,multirow,morefloats,floatflt,cancel,tfrupee}
\makeatletter


\AtBeginDocument{\@ifpackageloaded{textcomp}{}{\usepackage{textcomp}}}
\makeatother
\usepackage{colortbl}
\usepackage{xcolor}
\usepackage{pifont}
\usepackage[nointegrals]{wasysym}
\urlstyle{rm}
\makeatletter

%%%For Table column width calculation.
\def\mcWidth#1{\csname TY@F#1\endcsname+\tabcolsep}

%%Hacking center and right align for table
\def\cAlignHack{\rightskip\@flushglue\leftskip\@flushglue\parindent\z@\parfillskip\z@skip}
\def\rAlignHack{\rightskip\z@skip\leftskip\@flushglue \parindent\z@\parfillskip\z@skip}

%Etal definition in references
\@ifundefined{etal}{\def\etal{\textit{et~al}}}{}


%\if@twocolumn\usepackage{dblfloatfix}\fi
\usepackage{ifxetex}
\ifxetex\else\if@twocolumn\@ifpackageloaded{stfloats}{}{\usepackage{dblfloatfix}}\fi\fi

\AtBeginDocument{
\expandafter\ifx\csname eqalign\endcsname\relax
\def\eqalign#1{\null\vcenter{\def\\{\cr}\openup\jot\m@th
  \ialign{\strut$\displaystyle{##}$\hfil&$\displaystyle{{}##}$\hfil
      \crcr#1\crcr}}\,}
\fi
}

%For fixing hardfail when unicode letters appear inside table with endfloat
\AtBeginDocument{%
  \@ifpackageloaded{endfloat}%
   {\renewcommand\efloat@iwrite[1]{\immediate\expandafter\protected@write\csname efloat@post#1\endcsname{}}}{\newif\ifefloat@tables}%
}%

\def\BreakURLText#1{\@tfor\brk@tempa:=#1\do{\brk@tempa\hskip0pt}}
\let\lt=<
\let\gt=>
\def\processVert{\ifmmode|\else\textbar\fi}
\let\processvert\processVert

\@ifundefined{subparagraph}{
\def\subparagraph{\@startsection{paragraph}{5}{2\parindent}{0ex plus 0.1ex minus 0.1ex}%
{0ex}{\normalfont\small\itshape}}%
}{}

% These are now gobbled, so won't appear in the PDF.
\newcommand\role[1]{\unskip}
\newcommand\aucollab[1]{\unskip}
  
\@ifundefined{tsGraphicsScaleX}{\gdef\tsGraphicsScaleX{1}}{}
\@ifundefined{tsGraphicsScaleY}{\gdef\tsGraphicsScaleY{.9}}{}
% To automatically resize figures to fit inside the text area
\def\checkGraphicsWidth{\ifdim\Gin@nat@width>\linewidth
	\tsGraphicsScaleX\linewidth\else\Gin@nat@width\fi}

\def\checkGraphicsHeight{\ifdim\Gin@nat@height>.9\textheight
	\tsGraphicsScaleY\textheight\else\Gin@nat@height\fi}

\def\fixFloatSize#1{}%\@ifundefined{processdelayedfloats}{\setbox0=\hbox{\includegraphics{#1}}\ifnum\wd0<\columnwidth\relax\renewenvironment{figure*}{\begin{figure}}{\end{figure}}\fi}{}}
\let\ts@includegraphics\includegraphics

\def\inlinegraphic[#1]#2{{\edef\@tempa{#1}\edef\baseline@shift{\ifx\@tempa\@empty0\else#1\fi}\edef\tempZ{\the\numexpr(\numexpr(\baseline@shift*\f@size/100))}\protect\raisebox{\tempZ pt}{\ts@includegraphics{#2}}}}

%\renewcommand{\includegraphics}[1]{\ts@includegraphics[width=\checkGraphicsWidth]{#1}}
\AtBeginDocument{\def\includegraphics{\@ifnextchar[{\ts@includegraphics}{\ts@includegraphics[width=\checkGraphicsWidth,height=\checkGraphicsHeight,keepaspectratio]}}}

\DeclareMathAlphabet{\mathpzc}{OT1}{pzc}{m}{it}

\def\URL#1#2{\@ifundefined{href}{#2}{\href{#1}{#2}}}

%%For url break
\def\UrlOrds{\do\*\do\-\do\~\do\'\do\"\do\-}%
\g@addto@macro{\UrlBreaks}{\UrlOrds}



\edef\fntEncoding{\f@encoding}
\def\EUoneEnc{EU1}
\makeatother
\def\floatpagefraction{0.8} 
\def\dblfloatpagefraction{0.8}
\def\style#1#2{#2}
\def\xxxguillemotleft{\fontencoding{T1}\selectfont\guillemotleft}
\def\xxxguillemotright{\fontencoding{T1}\selectfont\guillemotright}

\newif\ifmultipleabstract\multipleabstractfalse%
\newenvironment{typesetAbstractGroup}{}{}%

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%

\usepackage[authoryear]{natbib}



\newif\ifnokeywords\nokeywordsfalse

\makeatletter\input{size10-pointfive.clo}\makeatother%
\definecolor{kwdboxcolor}{RGB}{242,242,242}
\usepackage[hidelinks,colorlinks=true,allcolors=blue]{hyperref}
\linespread{1}                 
\def\floatpagefraction{0.8}

\usepackage[paperheight=11.69in,paperwidth=8.26in,top=1in,bottom=1in,left=1in,right=.75in,headsep=24pt]{geometry}

\usepackage{multirow-custom}

\makeatletter

\def\hlinewd#1{%
  \noalign{\ifnum0=`}\fi\hrule \@height #1%
  \futurelet\reserved@a\@xhline}
\def\tbltoprule{\hlinewd{1pt}\\[-14pt]}
\def\tblbottomrule{\noalign{\vspace*{6pt}}\hline\noalign{\vspace*{2pt}}}
\def\tblmidrule{\hline\noalign{\vspace*{2pt}}}



\let\@articleType\@empty
\let\@journalDoi\@empty
\let\@journalVolume\@empty
\let\@journalIssue\@empty
\let\@crossMarkLink\@empty
\let\@receivedDate\@empty
\let\@acceptedDate\@empty
\let\@revisedDate\@empty
\let\@publishedDate\@empty
\let\@copyrightYear\@empty
\let\@firstPage\@empty
\def\articleType#1{\gdef\@articleType{#1}}
\def\journalDoi#1{\gdef\@journalDoi{#1}}
\def\crossMarkLink#1{\gdef\@crossMarkLink{#1}}
\def\receivedDate#1{\gdef\@receivedDate{#1}}
\def\acceptedDate#1{\gdef\@acceptedDate{#1}}
\def\revisedDate#1{\gdef\@revisedDate{#1}}
\def\publishedDate#1{\gdef\@publishedDate{#1}}
\def\copyrightYear#1{\gdef\@copyrightYear{#1}}
\def\journalVolume#1{\gdef\@journalVolume{#1}}
\def\journalIssue#1{\gdef\@journalIssue{#1}}
\def\firstPage#1{\gdef\@firstPage{#1}}
\let\@issuelogo\@empty%
\let\@issuelogoex\@empty%
\def\issuelogo#1{\gdef\@issuelogo{#1}}
\def\issuelogoex#1{\gdef\@issuelogoex{#1}}


\def\author#1{%
  \gdef\@author{%
    \hskip-\dimexpr(\tabcolsep)\hskip5pt%
    \parbox{\dimexpr\textwidth-1pt}%
    {\fontsize{11}{13}\selectfont\raggedright #1}%
  }%
}


\usepackage{pharmascope-abs}
\usepackage{caption}
\usepackage{lastpage}
\usepackage{fancyhdr}
\usepackage[noindentafter,explicit]{titlesec}
\usepackage{fontspec}

\setmainfont[%
BoldFont=cambriab.ttf,%
ItalicFont=CAMBRIAI.TTF,%
BoldItalicFont=CAMBRIAZ.TTF]{Cambria.ttf}
\lefthyphenmin = 3

\def\title#1{%
  \gdef\@title{%
      \vspace*{-40pt}%
       \ifx\@articleType\@empty\else{\fontsize{10}{12}\scshape\selectfont\hspace{8pt}\@articleType\hfill\mbox{}\par\vspace{2pt}}\fi%
       \minipage{\linewidth}
         \hrulefill\\[-0.7pt]%%{\includegraphics[width=75pt,height=50pt]{ijrps_logo.png}}\hfill
         \mbox{~}\hspace{5pt}\parbox{.1\linewidth}{\IfFileExists{images/\@issuelogo.\@issuelogoex}{\includegraphics[width=79pt,height=61pt]{images/\@issuelogo.\@issuelogoex}}{\includegraphics[width=75pt,height=50pt]{ijrps_logo.png}}}\hfill
         \fcolorbox{kwdboxcolor}{kwdboxcolor}{\parbox{.792\linewidth}{%
          \begin{center}\fontsize{17}{17}\selectfont\scshape\vskip-7pt International Journal of Research in Pharmaceutical Sciences\hfill\end{center}%
          \vspace*{-10pt}\hspace*{4pt}{\fontsize{8}{9}\selectfont Published by JK Welfare \& Pharmascope Foundation\hfill  Journal Home Page: \href{www.ijrps.com}{\color{blue}\underline{\smash{www.ijrps.com}}}}\hspace*{4pt}\mbox{}}}%
       \par\vspace*{-1pt}\rule{\linewidth}{1.3pt}%
       \endminipage%
    \par\vspace*{9.2pt}\parbox{.98\linewidth}{\linespread{.9}\raggedright\fontsize{14}{17}\selectfont #1}%
    \vspace*{-8pt}%
  }
}


\setlength{\parindent}{0pt}
\setlength{\parskip}{0.4pc plus 1pt minus 1pt}

\def\abbrvJournalTitle{Int. J. Res. Pharm. Sci.}

\fancypagestyle{headings}{%
  \renewcommand{\headrulewidth}{0pt}%
  \renewcommand{\footrulewidth}{0.3pt}
  \fancyhf{}%
  \fancyhead[R]{%
    \fontsize{9.12}{11}\selectfont\RunningAuthor,\ \abbrvJournalTitle,\ \ifx\@journalVolume\@empty X\else\@journalVolume\fi%
    \ifx\@journalIssue\@empty\else(\@journalIssue)\fi%
    ,\ \ifx\@firstPage\@empty 1\else\@firstPage\fi-\pageref*{LastPage}%
  }%
  \fancyfoot[LO,RE]{\fontsize{9.12}{11}\selectfont\textcopyright\ International Journal of Research in Pharmaceutical Sciences}%
  \fancyfoot[RO,LE]{\fontsize{9.12}{11}\selectfont\thepage}
}\pagestyle{headings}

                                                         
\fancypagestyle{plain}{%
  \renewcommand{\headrulewidth}{0pt}%
  \renewcommand{\footrulewidth}{0.3pt}%
  \fancyhf{}%
  \fancyhead[R]{%
    \fontsize{9.12}{11}\selectfont\RunningAuthor,\ \abbrvJournalTitle,\ \ifx\@journalVolume\@empty X\else\@journalVolume\fi%
    \ifx\@journalIssue\@empty\else(\@journalIssue)\fi%
    ,\ \ifx\@firstPage\@empty 1\else\@firstPage\fi-\pageref*{LastPage}%
  }%
  \fancyfoot[LO,RE]{\fontsize{9.12}{11}\selectfont\textcopyright\ International Journal of Research in Pharmaceutical Sciences}%
  \fancyfoot[RO,LE]{\fontsize{9.12}{11}\selectfont\thepage}
  \ifx\@firstPage\@empty\else\setcounter{page}{\@firstPage}\fi
}


\def\NormalBaseline{\def\baselinestretch{1.1}}
\usepackage{textcase}
\setcounter{secnumdepth}{0}

\titleformat{\section}[block]{\bfseries\boldmath\NormalBaseline\filright\fontsize{10.5}{13}\selectfont}
{\thesection}
{6pt}
{\MakeTextUppercase{#1}}
[]
\titleformat{\subsection}[block]{\bfseries\boldmath\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubsection}
{6pt}
{#1}
[]
\titleformat{\subsubsection}[block]{\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubsubsection}
{6pt}
{#1}
[]
\titleformat{\paragraph}[block]{\NormalBaseline\filright\fontsize{10.5}{10}\selectfont}
{\theparagraph}
{6pt}
{#1}
[]
\titleformat{\subparagraph}[block]{\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubparagraph}
{6pt}
{#1}
[]

\titlespacing{\section}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subsection}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subsubsection}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\paragraph}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subparagraph}{0pt}{.5\baselineskip}{.5\baselineskip}

\captionsetup[figure]{skip=1.4pt,font=bf,labelsep=colon,justification=raggedright,singlelinecheck=false}
\captionsetup[table]{skip=1.4pt,font=bf,labelsep=colon,justification=raggedright,singlelinecheck=false}

\def\bibyear#1{#1}
%\def\bibjtitle#1{#1}   %%Publisher request
\def\bibauand{}
\setlength\bibsep{3pt}
\setlength\bibhang{8pt}

\makeatother
\date{}


\begin{document}


\def\RunningAuthor{Ranjit S. Ambad et al.}
\firstPage{2701}
\articleType{Original Article}
\receivedDate{14 Apr 2020}
\acceptedDate{14 May 2020}
\revisedDate{02 May 2020}
\journalVolume{2020, 11}
\journalIssue{2}
\journalDoi{ijrps.v11i2.2290}
\copyrightYear{2020}
\def\authorCount{5}
\def\affCount{4}

\def\journalTitle{International Journal of Research in Pharmaceutical Sciences}

\title{To study the effect of oral vitamin D supplements on wound healing in patient with diabetic foot ulcer and its effect on lipid metabolism}
\author{Ajoinish~Kamble\textsuperscript{1},  
            Ranjit~S.~Ambad\textsuperscript{*}\textsuperscript{2},  
            Mangesh~Padamwar\textsuperscript{3},  
            Anupam~Kakade\textsuperscript{3}, 
            Meenakshi~Yeola\textsuperscript{4}~\\[5pt]{\textsuperscript{1}Department of Surgery, Datta Meghe Medical College, Shalinitai Meghe Hospital \& Research Centre, Hingana, Nagpur, Maharashtra, India}~\\{\textsuperscript{2}Department of Biochemistry, Datta Meghe Medical College, Shalinitai Meghe Hospital \& Research Centre, Hingana, Nagpur, Maharashtra, India}~\\{\textsuperscript{3}Department of General Surgery, Datta Meghe Medical College, Shalinitai Meghe Hospital and Research Centre (Datta Meghe Institute of Medical Sciences), Hingana, Nagpur-441110, India}~\\{\textsuperscript{4}Department of General Surgery,  Jawaharlal Nehru Medical College, (Datta Meghe Institute of Medical Sciences), Sawangi Meghe Wardha, India}}

\begin{abstract}
To Critically Assess the effect of oral vitamin D supplements on wound healing in patient with diabetic foot ulcer and its effect on lipid metabolism.This is a single-Centre prospective randomized, control-controlled study was conducted in Department of Surgery Datta Meghe Medical College, Hingna, Nagpur, in collaboration with Datta Meghe Institute of Medical Sciences (DMIMS) Deemed to be University from June 2019 TO March 2020. Total 60 patients were included in this study randomized grouping were done, group A vitamin d supplements and group B as control group.In group A vitamin D levels were significantly increased after 12 weeks of intervention as compared to baseline while in group B no change was seen after intervention. After 12 week of intervention, comparison of group A vs. group B, we found that Vitamin D HbA1c, TC, HDL and Wound surface area, significantly improved while there was no change seen in triglycerides levels in both the group.After intervention with vitamin D supplements for 12 weeks among patients with diabetic foot ulcer had good result and beneficial effect on glucose metabolism, vitamin D levels, lipid profile and wound healing.
\end{abstract}\def\keywordstitle{Keywords}

\begin{keywords}Vit D,\newline TCH,\newline TG,\newline HDL and diabetic foot ulcer
\end{keywords}
\twocolumn[ \maketitle {\printKwdAbsBox}]
\makeatletter{\raggedright\textsuperscript{*}Corresponding Author\par Name:\ Ranjit~S.~Ambad~\\ Phone:\ 9890959395~\\  Email:\ Ambad.sawan@gmail.com
        \par}\vspace*{-11pt}\hrulefill\par{\fontsize{12}{14}\selectfont ISSN: 0975-7538}\par% 
        \textsc{DOI:}\ \href{https://doi.org/10.26452/\@journalDoi}{\textcolor{blue}{\underline{\smash{https://doi.org/10.26452/\@journalDoi}}}}\par%
        \vspace*{-11pt}\hrulefill\\{\fontsize{9.12}{10.12}\selectfont Production and Hosted by}\par{IJRPS |~\href{www.ijrps.com}{www.ijrps.com}}\par%
        \vspace*{-2pt}{\fontsize{9.12}{10.12}\selectfont\textcopyright\ \@copyrightYear\ $|$ All rights reserved.}\par%
        \vspace*{-11pt}\rule{\linewidth}{1.2pt}
        \makeatother
        
    
\section{Introduction}
 Diabetes mellitus is major problem in worldwide in year 2015, 415 million population were known to have diabetes mellitus. There is increase in diabetic population around 642 million approximately by year 2040 \unskip~\citep{798471:19050711}. 69.2 million Population are affected in India, according to recent estimate \unskip~\citep{798471:19050711}. Complication of diabetes mellitus leading to 5 million deaths globally in 2015 \unskip~\citep{798471:19050718}. As complication of diabetes mellitus leads to increase morbidity, mortality and health expenditure \unskip~\citep{798471:19050721}. 

 Diabetic foot is one of the most significant and devastating complications of diabetes and is characterized as a group of syndromes with neuropathy, ischemia and infection leading to tissue breakdown and eventual amputation\unskip~\citep{798471:19050712}. Diabetic patients are at greater risk of developing Diabetic foot infection and ulcer formation and leading to non-traumatic amputation of foot. It is estimated that approximately 45,000 lower limbs are amputated every year in India and the vast majority of these are probably preventable \unskip~\citep{798471:19050724}. Vitamin D has immunomodulatory role with homeostasis of calcium and bone metabolism \unskip~\citep{798471:19050726,798471:19050727}. Vitamin D has direct effect on the function of the pancreatic cells and treatment with vitamin D supplements wound improve in glucose induce insulin secretion \unskip~\citep{798471:19050720}. Foot infection accounts for 20 \% of hospitalisation of diabetic patients annually \unskip~\citep{798471:19050719}. Immunological defects in addition to neuropathy and vascular abnormality are the prime contributors in the pathogenesis of diabetic foot and subsequent infections \unskip~\citep{798471:19050715}. Different studies have shown that deficiency of vitamin D leads to immune cell dysfunction, b cell damage and impaired insulin production. In addition to hyperglycaemia, vitamin D deficiency could also be linked to an altered immune system of patients with diabetes, rendering them susceptible to foot infection and unfavourable prognosis\unskip~\citep{798471:19050714,798471:19050716,798471:19050723}. 

So we design this study to evaluate the effect of vitamin D supplements for 12 week in diabetic foot ulcer patient with grade II and grade III wagner diabetic foot ulcer classification comparing with control group.  


\begin{table*}[!htbp]
\caption{\boldmath {General characteristics of study participants} }
\label{tw-58e57a0281bf}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.6056999999999999\linewidth-2\tabcolsep}p{\dimexpr.21190000000000015\linewidth-2\tabcolsep}p{\dimexpr.18239999999999995\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor} & Group A \mbox{}\protect\newline Vitamin D  \mbox{}\protect\newline group(n=30) & Group B \mbox{}\protect\newline control group(n=30)\\
\tblmidrule 
Gender (\%) &
   &
  \\
Male &
  25(80\%) &
  23 (69.57\%)\\
Female &
  5 (20\%) &
  7 (30.43\%)\\
Age (years) &
  60.2\ensuremath{\pm}9.3 &
  59.7\ensuremath{\pm}8.4\\
Height (cm) &
  172.7\ensuremath{\pm}14.7 &
  169.4\ensuremath{\pm}12.5\\
Weight at start of trial (kg) &
  78.6\ensuremath{\pm}12.9 &
  74.2\ensuremath{\pm}15.5\\
Weight at end of trial (kg) &
  78.5\ensuremath{\pm}12.8 &
  74.1\ensuremath{\pm}15.6\\
Weight change (kg) &
  0.01\ensuremath{\pm}0.6 &
  0.01\ensuremath{\pm}1.1\\
BMI at start of trial (Kg/m2) &
  26.4\ensuremath{\pm}4.2 &
  25.9\ensuremath{\pm}3.8\\
BMI at end if trial (Kg/m2) &
  26.4\ensuremath{\pm}4.1 &
  25.9\ensuremath{\pm}3.9\\
BMI change &
  0.001\ensuremath{\pm}0.04 &
  0.006\ensuremath{\pm}0.02\\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}
\textbf{Aim}

To Critically Assess the effect of oral vitamin D supplements on wound healing in patient with diabetic foot ulcer and its effect on lipid metabolism.\textbf{\space }

\textbf{Objective}

This study is conducted to evaluate the effect of oral vitamin D supplements on wound healing inpatient with diabetic foot ulcer.

To study the effect of oral vitamin D supplements on lipid profile.


\begin{table*}[!htbp]
\caption{\boldmath {Wound healing, metabolic bio markers, at baseline and 12 weeks of intervention in patients with diabetic foot ulcer} }
\label{tw-e4580e49f051}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.279\linewidth-2\tabcolsep}p{\dimexpr.2193\linewidth-2\tabcolsep}p{\dimexpr.189\linewidth-2\tabcolsep}p{\dimexpr.1682\linewidth-2\tabcolsep}p{\dimexpr.1445\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor} & \multicolumn{4}{p{\dimexpr(.721\linewidth-2\tabcolsep)}}{\cAlignHack Group A [Vitamin D group (n=30)]}\\
\rowcolor{kwdboxcolor} & Baseline & End of trial & Change & P Value\\
\tblmidrule 
Vitamin D (ng/ml) &
  18.5\ensuremath{\pm}11.6 &
  31\ensuremath{\pm}9.8 &
  -12.5\ensuremath{\pm}10.1 &
  0.0001\\
HbA1c (\%) &
  9.1\ensuremath{\pm}2.1 &
  7.9\ensuremath{\pm}2.7 &
  1.2\ensuremath{\pm}0.03 &
  0.008\\
TG (mg/dl) &
  169.6\ensuremath{\pm}54.4 &
  150.7\ensuremath{\pm}50.3 &
  18.8\ensuremath{\pm}51.6 &
  0.167\\
T C (mg/dl) &
  180.8\ensuremath{\pm}30.3 &
  165.5\ensuremath{\pm}30.7 &
  15.1 0.07  &
  0.05\\
HDL (mg/dl) &
  34.8\ensuremath{\pm}3.8 &
  36.1\ensuremath{\pm}2.4 &
  -1.3\ensuremath{\pm}1.2 &
  0.118\\
WSA &
  29.83\ensuremath{\pm}15.02 &
  21.76\ensuremath{\pm}11.30 &
  8.06\ensuremath{\pm}6.82 &
  0.02\\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}

    
\section{Materials and Methods}
\textbf{Study Setting}

This is a single-Centre prospective randomized, control-controlled study was conducted in Department of Surgery Datta Meghe Medical College Hingna, Nagpur in collaboration with Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Sawangi, Wardha, Maharashtra, come under Datta Meghe Institute of Medical Sciences (DMIMS) Deemed to be University. 

\textbf{Duration of study}

June 2019 TO March 2020. 

\textbf{Sample size}

Total 60 patients were included in this study.

\textbf{Grouping }

Randomized Grouping.

Group A- vitamin D supplements

Group B- control group

\textbf{Selection criteria}

\textbf{Inclusion Criteria for the Study}

Diabetic patients with grades II/ III-foot ulcer

\textbf{Exclusion Criteria for the Study}

Nondiabetic ulcer 

Patients with chronic kidney disease (CKD) 

Taking immunosuppressant, Calcium supplements and drugs that interfere with vitamin D metabolism.

Liver diseases.

Wagner's grade I, IV and V ulcer.

Lost to follow up.


\begin{table*}[!htbp]
\caption{\boldmath {Wound healing, metabolic bio markers, at baseline and 12 weeks of intervention in control group} }
\label{tw-216b6c3dccfa}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.31360000000000003\linewidth-2\tabcolsep}p{\dimexpr.18610000000000003\linewidth-2\tabcolsep}p{\dimexpr.1821\linewidth-2\tabcolsep}p{\dimexpr.1777\linewidth-2\tabcolsep}p{\dimexpr.1405\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor} & \multicolumn{4}{p{\dimexpr(.6864\linewidth-2\tabcolsep)}}{\cAlignHack Group B [Control group (n=30)]}\\
\rowcolor{kwdboxcolor} & Baseline & End of trial & Change & P Value\\
\tblmidrule 
Vitamin D (ng/ml) &
  20.5\ensuremath{\pm}9.3 &
  20.1\ensuremath{\pm}8.5 &
  0.4\ensuremath{\pm}0.3 &
  0.86\\
HbA1c (\%) &
  9.8\ensuremath{\pm}3.5 &
  9.9\ensuremath{\pm}4.8 &
  -0.1\ensuremath{\pm}0.8 &
  0.92\\
Triglycerides (mg/dl) &
  159.4\ensuremath{\pm}68.8 &
  155.9\ensuremath{\pm}70.5 &
  3.8\ensuremath{\pm}6.4 &
  0.846\\
Total cholesterol (mg/dl) &
  172.4\ensuremath{\pm}38.2 &
  179.2\ensuremath{\pm}40.6 &
  -6.6\ensuremath{\pm}2.2 &
  0.5\\
HDL (mg/dl) &
  37.6\ensuremath{\pm}4.6 &
  32.6\ensuremath{\pm}5.1 &
  5.1\ensuremath{\pm}1.3 &
  0.002\\
WSA &
  25.06\ensuremath{\pm}14.02 &
  21.3\ensuremath{\pm}13.19 &
  3.76\ensuremath{\pm}1.73 &
  0.28\\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}
\textbf{Trial design}

The current study was a prospective randomized controlled clinical trail

 \textbf{Participants}

60 patients with grade II/III patients, between 2019 to 2020.

\textbf{Study design }

All participants were stratified for gender, type and duration of DM. Participants were randomly divided into two groups group A received vitamin D supplements every weekly for 12 weeks. Participants were followed-up at every weekly for 12 weeks for assessment of wound healing and vitamin D supplements. Group B were monitored every weekly and no medication were given that wound interfere in vitamin D metabolism.

\textbf{Intervention}

Patient received supplements every weekly for 12 weeks. Group A received cholecalciferol 60000 IU sachet and no medication were given to control group that wound interfere the vitamin D metabolism.

The data was collected from 60 patients with diabetic ulcers satisfying all the inclusion criteria mentioned above. Selection of patients was done from consecutive series of prospective patients. Randomized grouping was done, Group A as a vitamin D supplements and group B as control. Informed written consent was obtained from all participants. A detailed clinical history, including age, sex, height, weight, BMI calculation done at start and end of trial, duration of diabetes, wound surface area was taken on baseline and end of trial and concomitant and anti-diabetic medications, was recorded on a preset proforma. Patient were followed or examined for 12 weeks after standard care and Wound healing rate was assessed by change in surface area and calculated by below mentioned formula,
\begin{eqnarray*}Surface\;area\;change\;\triangle A\;=Aa-Ab \end{eqnarray*}
Where, Aa = wound area on admission 

Ab=wound area on 12 weeks
\begin{eqnarray*}BMI\;(\%)=\frac{Kg}{m^{2}}\times100 \end{eqnarray*}
Where, kg= weight of patient

M\ensuremath{^{2}}= height of patient (cm)

WSA= wound surface area

\textbf{Sample collection}

Blood samples with and without anti-coagulant was collected for estimating glycosylated HbA1c and serum 25-hydroxyvitamin D (25(OH) D), Lipid Profile, respectively.

\textbf{Serum 25-hydroxyvitamin D assay}

Serum 25(OH)D was estimated by Radioimmunoassay (RIA)

\textbf{Adequacy of vitamin D}

Different cut-offs of vitamin D level for deficiency is chosen, i.e., \ensuremath{\leq }25 (severe), \ensuremath{\leq }50(moderate) and \ensuremath{\leq }75(mild) nmol/l for evaluating the most appropriate risk factor in patients with diabetic foot infection. The three cut-offs of vitamin D deficiency chosen are in accordance with the recommendation of Endocrine Society practice guidelines \unskip~\citep{798471:19050723} and Institute of Medicine definitions \unskip~\citep{798471:19050722}. 

\textbf{The Wagner Diabetic Foot Ulcer Grade Classification System}

The Wagner diabetic foot ulcer classification system assesses ulcer depth and the presence of osteomyelitis or gangrene by using the following grades:


  
  \begin{enumerate}
  \item \relax Grade 0 {\textendash} intact Skin
  \item \relax Grade 1 {\textendash} superficial ulcer of skin or subcutaneous tissue
  \item \relax Grade 2 {\textendash} ulcers extend into tendon, bone, or capsule
  \item \relax Grade 3 {\textendash} deep ulcer with osteomyelitis, or abscess
  \item \relax Grade 4 {\textendash} partial foot gangrene
  \item \relax Grade 5 {\textendash} whole foot gangrene
  \end{enumerate}
  \textbf{Statistical Analysis}

\textbf{\space }Data collected was entered into Microsoft Excel Worksheet and statistically analysed by using SPSS (Statistical Package for Social Sciences) version 20. For quantitative data mean, standard mean, standard deviation, t-test and Karl Pearson's Coefficient of Correlation were calculated. P value \textless\ 0.05 (0.01) will be considered as statically significant (highly significant) at 95\% confidence interval.

\textbf{Ethical Consideration}

\textbf{\space }Informed and written consent (Marathi and English) was taken from each subject before collecting data and blood sample. Only those individuals, who volunteer to participate in the study, was included and the data was kept confidential. The study was not imposing any burden on the subjects and the Institute; therefore, the study is ethically justified. The proposed study was undertaken subject to approval by Institutional Ethical Committee.


\begin{table*}[!htbp]
\caption{\boldmath {Changes in wound surface area and change in metabolic bio markers after intervention for 12 weeks} }
\label{tw-364f26aaa309}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.3245\linewidth-2\tabcolsep}p{\dimexpr.28119999999999997\linewidth-2\tabcolsep}p{\dimexpr.26220000000000006\linewidth-2\tabcolsep}p{\dimexpr.1321\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}Parameters & Group A \mbox{}\protect\newline Vitamin D group & Group B \mbox{}\protect\newline Control group & P Value\\
\tblmidrule 
Vitamin D &
  12.5\ensuremath{\pm}10.1 &
  0.4\ensuremath{\pm}0.3 &
  0.0001\\
HbA1c &
  1.2\ensuremath{\pm}0.03 &
  0.1\ensuremath{\pm}0.8 &
  0.0001\\
Triglycerides &
  18.5\ensuremath{\pm}51.6 &
  3.8\ensuremath{\pm}6.4 &
  0.126\\
Total cholesterol &
  15.1 0.07  &
  6.6\ensuremath{\pm}2.2 &
  0.0001\\
HDL &
  1.3\ensuremath{\pm}1.2 &
  5.1\ensuremath{\pm}1.3 &
  0.0001\\
WSA after 12 weeks &
  8.06\ensuremath{\pm}6.82 &
  3.76\ensuremath{\pm}1.73 &
  0.0014\\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}

    
\section{ Results and Discussion}
Table~\ref{tw-58e57a0281bf} shows the demographic characteristic of two groups. In vitamin D group males were 25 and females were 5 out of 25 while in control group males were 23 and females were 7 respectively. Mean age was 60.2\ensuremath{\pm}9.3 in group A and 59.7\ensuremath{\pm}8.4 in group B, height was 172.7\ensuremath{\pm}14.7 in group A and 169.4\ensuremath{\pm}12.5 in group B respectively. In group A mean weight of patient at baseline was 78.6\ensuremath{\pm}12.9 and at the end of trial was 78.5\ensuremath{\pm}12.8, while in group B baseline was74.2\ensuremath{\pm}15.5 and at the end of trial was 74.1\ensuremath{\pm}15.6. Weight change was 0.01\ensuremath{\pm}0.6 and 0.01\ensuremath{\pm}1.1 in group A and B respectively. In group A, BMI at baseline and end of trial was 26.4\ensuremath{\pm}4.2 and 26.4\ensuremath{\pm}4.1, while change was 0.001\ensuremath{\pm}0.04. In group B, BMI at baseline and end of trial was 25.9\ensuremath{\pm}3.8 and 25.9\ensuremath{\pm}3.9, while change was 0.001\ensuremath{\pm}0.04 respectively.

Table~\ref{tw-e4580e49f051}  shows in group A vitamin D levels were significantly increased after 12 weeks of intervention as compared to baseline (18.5\ensuremath{\pm}11.6 vs. 31\ensuremath{\pm}9.8, p=0.0001). There was significant change in HbA1c level after intervention in group A (9.1\ensuremath{\pm}2.1 vs. 7.9\ensuremath{\pm}2.7, p=0.008). Similar results were seen in total cholesterol levels after intervention in group A (180.8\ensuremath{\pm}30.3 vs. 165.5\ensuremath{\pm}30.7, p=0.05). Wound surface area was (29.83\ensuremath{\pm}15.02 vs. 21.76\ensuremath{\pm}11.30, p=0.02) in group A. The level of high-density lipoprotein in group A (34.8\ensuremath{\pm}3.8 vs. 36.1\ensuremath{\pm}2.4, p=0.118) after 12 weeks of intervention. High density lipoprotein in group A was 34.8\ensuremath{\pm}3.8 in baseline and at the end of trial was 36.1\ensuremath{\pm}2.4 and change was -1.3\ensuremath{\pm}1.2 and no significant change was observed p value is 0.118.

Table~\ref{tw-216b6c3dccfa} shows in group B no change was seen after intervention (20.5\ensuremath{\pm}9.3 vs. 20.1\ensuremath{\pm}8.5, p=0.86). HbA1c level after intervention in was group B (9.8\ensuremath{\pm}3.5 vs. 9.9\ensuremath{\pm}4.8, p=0.92). Total cholesterol levels after intervention in group B (172.4\ensuremath{\pm}38.2 vs. 179.2\ensuremath{\pm}40.6, p=0.5). Wound surface area was in group B (25.06\ensuremath{\pm}14.02 vs. 21.3\ensuremath{\pm}13.19, p=0.28). The level of high-density lipoprotein in group B (37.6\ensuremath{\pm}4.6 vs. 32.6\ensuremath{\pm}5.1, p=0.002) was significantly lower level after 12 weeks of intervention. No significant changes were seen in triglycerides level group B.

Table~\ref{tw-364f26aaa309} shows change after 12 weeks of intervention. After 12 week of intervention, comparison of group A vs. group B, we found that Vitamin D (12.5\ensuremath{\pm}10.1 vs. 0.4\ensuremath{\pm}0.3, p=0.0001), Glycoslated hemoglobin (1.2\ensuremath{\pm}0.03 vs. 0.1\ensuremath{\pm}0.8, p=0.0001), Total cholesterol (15.1 0.07 vs. 6.6\ensuremath{\pm}2.2, p=0.0001), High density lipoprotein (1.3\ensuremath{\pm}1.2 vs. 5.1\ensuremath{\pm}1.3, p=0.0001) and Wound surface area (8.06\ensuremath{\pm}6.82 vs. 5.1\ensuremath{\pm}1.3, p=0.0001), significantly improved while there was no change seen in triglycerides levels (18.5\ensuremath{\pm}51.6 vs. 3.8\ensuremath{\pm}6.4, p=0.126) in both the group.

In our study, we study the effect of vitamin D supplements in diabetic foot ulcer patients. We supplemented patients with oral cholecalciferol sachet (60,000-IU) every weekly for 12 week and patients were followed up every weekly for supplements and for examination. Control groups were not given any medication which will interfere with vitamin D metabolism. After 12 weeks of intervention, we evaluated wound surface area, lipid concentration (total cholesterol, triglyceride and high-density lipoprotein) and glycoslated hemoglobin.

Vitamin D levels (12.5\ensuremath{\pm}10.1 vs. 0.4\ensuremath{\pm}0.3, p=0.0001) significantly raised after intervention for 12 weeks. In this study we found that vitamin D supplements had beneficial effect on wound surface area as compared to control group (8.06\ensuremath{\pm}6.82 vs. 5.1\ensuremath{\pm}1.3, p=0.0001), there was marked reduction in size of wound surface area. There was significant decrease in level of glycoslated hemoglobin (1.2\ensuremath{\pm}0.03 vs. 0.1\ensuremath{\pm}0.8, p=0.0001) after intervention. We found significant decrease in total cholesterol levels (15.1 0.07 vs. 6.6\ensuremath{\pm}2.2, p=0.0001). Levels of high-density lipoproteins were elevated in group A as compared to group B (1.3\ensuremath{\pm}1.2 vs. 5.1\ensuremath{\pm}1.3, p=0.0001). No changes seen in triglycerides level in both groups. 

In our study, we found that patients in group A, vitamin D, glycosylated hemoglobin total cholesterol, high density lipoprotein significantly improved and significant reduction in wound surface area after intervention.

 Silimar effect are seen in few studies rezza razaghi et al vitamin D supplementation for 12 weeks in patients with DFU had beneficial effects on glucose homeostasis, lipid profile and reduction in diabetic foot ulcer size \unskip~\citep{798471:19050722}.

Silimar effects were observed by Hassan Mozaffari-Khosravi et al after intervention with injectable vitamin d, wound size significantly reduced and improves glucose metabolism and vitamin D levels. (2020) \unskip~\citep{798471:19050725}.

In our study we found that there was increase in vitamin D levels and decrease in glycosylated hemoglobin and decrease wound surface area after 12 week intervention, Hu, Zhiwei MM et al suggested that Vitamin D supplementation in diabetic mellitus patients can improve HbA1c, insulin resistance, and insulin in short-term intervention, suggesting that vitamin D can be considered as a therapeutic agent along with the other treatments for T2D. Studies have shown that vitamin D deficiency is associated with the development of T2D, T2D nephropathy, T2D microvascular or macrovascular disease, diabetic retinopathy, and diabetic peripheral neuropathy \unskip~\citep{798471:19050717,798471:19050713}.
    
\section{Conclusions}
Present study supports that vitamin D deficiency is more prominent in diabetic foot patients and impaired wound healing and glucose metabolism. After intervention with vitamin D supplements for 12 weeks among patients with diabetic foot ulcer had good result and beneficial effect on glucose metabolism, vitamin D levels, lipid profile and wound healing. The only limitation was that, this study had small sample size and diabetic subjects with diabetic foot ulcer. 

\textbf{Conflict of Interest}

Nil.

\textbf{Source of Funding}

Nil.
    

\bibliographystyle{pharmascope_apa-custom}

\bibliography{\jobname}
\end{document}
